zoldonrasib

DRUG4 trials

Sponsors

Revolution Medicines, Inc.

Conditions

Advanced Solid TumorsCRCColorectal Cancer (CRC)Lung Cancer (NSCLC)Metastatic NSCLC - Non-Small Cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung CancerMetastatic Solid TumorsNSCLC

Phase 1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

RecruitingNCT07397338

Revolution Medicines, Inc.Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC) +3

Start: 2026-01-30End: 2029-05-01Target: 370Updated: 2026-08-03

Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

RecruitingNCT07621718

Revolution Medicines, Inc.Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC +5

Start: 2026-05-22End: 2030-04-22Target: 670Updated: 2026-09-10

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

RecruitingNCT07777822

Revolution Medicines, Inc.NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC +4

Start: 2026-08-14End: 2031-02-01Target: 430Updated: 2026-08-20

Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

RecruitingNCT07805954

Revolution Medicines, Inc.Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC +5

Start: 2026-08-28End: 2030-04-01Target: 400Updated: 2026-09-08